Compounds that are ERK inhibitors

US8716483B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Alan B. Cooper · West Caldwell, US
• Yang Nan · Nanjing, CN
• Yongqi Deng · Newton, US
• Gerald W. Shipps, Jr. · Stoneham, US
• Neng-Yang Shih · Lexington, US
• Hugh Y. Zhu · Scotch Plains, US
• Jagdish A. Desai · Manalapan, US
• James Wang · Newark, US
• Sunil Paliwal · Manalapan, US
• Hon-Chung Tsui · East Brunswick Township, US
• Sobhana Babu Boga · Scotch Plains, US
• Abdul-Basit Alhassan · Scotch Plains, US
• Xiaolei Gao · Bound Brook, US
• Liang Zhu · Waltham, US
• Ahmed Abdi Samatar · Plainsboro, US

Key dates

• Filing date: Feb 19, 2009
• Grant date: May 6, 2014
• Expiry date: Apr 26, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.